文献速递心律失常

短联律间期室颤在不明原因心脏骤停中占6.6%且奎尼丁有效

Short-coupled ventricular fibrillation represents a distinct phenotype among latent causes of unexplained cardiac arrest: a report from the CASPER registry.
PubMed 文献 · Eur Heart J · 2021-01-01

CASPER注册研究纳入364例不明原因心脏骤停幸存者,按触发室早联律间期<350 ms定义短联律间期室颤(SCVF),24例(6.6%)符合诊断。SCVF患者电风暴发生率21%显著高于其他不明原因心脏骤停者,奎尼丁用于50%复发患者且心律失常控制良好。

要点

  • SCVF占不明原因心脏骤停至少6.6%,是独立原发性心律失常综合征。
  • SCVF诊断依赖记录到室颤起始,多数在复发心律失常时确诊。
  • 奎尼丁对SCVF复发有效,应考虑作为一线治疗。

核心结论

  • 短联律间期室颤是独立原发性心律失常综合征,占不明原因心脏骤停至少6.6%。
  • 奎尼丁对SCVF有效,应考虑作为复发患者的一线治疗。

研究设计与样本

  • 多中心研究,纳入CASPER注册中连续的不明原因心脏骤停幸存者364例。
  • SCVF定义为由联律间期<350 ms的触发室早启动的、其他原因无法解释的室颤。

主要发现

  • 364例中24例(6.6%)符合SCVF诊断标准。
  • 24例中19例(79%)通过随访中记录到室颤获得诊断。
  • 室性心律失常由平均联律间期274±32 ms的室早启动。
  • SCVF先证者电风暴发生率21%,不明原因心脏骤停先证者为0%(P<0.001)。
  • SCVF复发室性心律失常的中位时间为31个月,12/24例(50%)因复发室颤接受奎尼丁且心律失常控制良好。

关键数值与推荐

  • SCVF诊断标准:其他原因无法解释的室颤,由联律间期<350 ms的触发室早启动。
  • SCVF占不明原因心脏骤停的6.6%(24/364)。
  • SCVF先证者电风暴发生率21%,不明原因心脏骤停先证者为0%(P<0.001)。

临床怎么用

  • 对不明原因心脏骤停幸存者应评估触发室早联律间期以识别SCVF。
  • SCVF复发患者可考虑奎尼丁作为一线治疗。

局限性

  • 诊断需记录室颤起始,多数病例在复发心律失常时才确诊,真实患病率仍未知。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The term idiopathic ventricular fibrillation (IVF) describes survivors of unexplained cardiac arrest (UCA) without a specific diagnosis after clinical and genetic testing. Previous reports have described a subset of IVF individuals with ventricular arrhythmia initiated by short-coupled trigger premature ventricular contractions (PVCs) for which the term short-coupled ventricular fibrillation (SCVF) has been proposed. The aim of this article is to establish the phenotype and frequency of SCVF in a large cohort of UCA survivors. METHODS AND RESULTS: We performed a multicentre study including consecutive UCA survivors from the CASPER registry. Short-coupled ventricular fibrillation was defined as otherwise unexplained ventricular fibrillation initiated by a trigger PVC with a coupling interval of <350 ms. Among 364 UCA survivors, 24/364 (6.6%) met diagnostic criteria for SCVF. The diagnosis of SCVF was obtained in 19/24 (79%) individuals by documented ventricular fibrillation during follow-up. Ventricular arrhythmia was initiated by a mean PVC coupling interval of 274 ± 32 ms. Electrical storm occurred in 21% of SCVF probands but not in any UCA proband (P < 0.001). The median time to recurrent ventricular arrhythmia in SCVF was 31 months. Recurrent ventricular fibrillation resulted in quinidine administration in 12/24 SCVF (50%) with excellent arrhythmia control. CONCLUSION: Short-coupled ventricular fibrillation is a distinct primary arrhythmia syndrome accounting for at least 6.6% of UCA. As documentation of ventricular fibrillation onset is necessary for the diagnosis, most cases are diagnosed at the time of recurrent arrhythmia, thus the true prevalence of SCVF remains still unknown. Quinidine is effective in SCVF and should be considered as first-line treatment for patients with recurrent episodes.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Steinberg C, Davies B, Mellor G, et al. Short-coupled ventricular fibrillation represents a distinct phenotype among latent causes of unexplained cardiac arrest: a report from the CASPER registry. Eur Heart J. 2021. PMID: 34010395. doi:10.1093/eurheartj/ehab275

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。